Difference in revascularisation procedure rate after a STEMI event between migrants and the ethnic Dutch population ≥30 years of age (HR (95% CI))*.

<p>^† Adjusted for age, sex, and degree of urbanisation</p><p>^‡ Adjusted for age, sex, degree of urbanisation, and Charlson comorbidity index</p><p>x Adjusted for age, sex, degree of urbanisation, Charlson comorbidity index, and neighborhood SES</p><p>Difference in revascularisation procedure rate after a STEMI event between migrants and the ethnic Dutch population ≥30 years of age (HR (95% CI))*.</p

Characteristics of persons with a STEMI event ≥30 years of age in the Achmea Health Database between 2006 and 2011.

<p>* ST-elevation myocardial infarction</p><p>^† Percutaneous coronary intervention</p><p>^‡ Coronary artery bypass grafting</p><p>x Interquartile range</p><p>^§ Socioeconomic status</p><p>^ll Based on population density (number of residents per km²). Very urban = >2000, urban = 1001–2000, urban/rural = 501–1000, rural = 251–500, very rural = <251</p><p>^# At least one hospitalisation for a diagnosis included in the Charlson comorbidity index from 1995 until the STEMI event</p><p>** Not given in line with the Dutch data protection guideline as the number of cases was less than ten</p><p>Characteristics of persons with a STEMI event ≥30 years of age in the Achmea Health Database between 2006 and 2011.</p

Additional file 2: Table S2. of Prescription of secondary preventive drugs after ischemic stroke: results from the Malaysian National Stroke Registry

Factors related to the prescription of secondary preventive drugs among ischemic stroke patients by types of drugs (multivariable analysis). This table is similar to Fig. 3a–d but the estimates are provided in a table format. (DOCX 21 kb

Prevalence of cardiovascular medication on secondary prevention after myocardial infarction in China between 1995-2015: A systematic review and meta-analysis

<div><p>Background</p><p>Myocardial Infarction (MI) has become a major cause of morbidity and mortality in China, but little is known about the prevalence of guideline-recommended cardiovascular medications after MI events over the last two decades. This systematic review and meta-analysis aims to summarize cardiovascular medication use between 1995–2015 and to assess factors in associated with the trends in cardiovascular medications.</p><p>Method</p><p>A systematic search was conducted in four databases (Pubmed, Embase, CENTRAL, and CNKI) to obtain observational studies published between 1995 and 2015, reporting on the use of cardiovascular medications in China. Risk of bias of individual studies was appraised and selected studies were pooled for estimated prevalence of cardiovascular medication. Prevalence of cardiovascular medication use for 1995 and 2015 was estimated by random effects meta-regression model.</p><p>Results</p><p>From 13,940 identified publications, 35 studies, comprising 28,000 patients, were included. The pooled prevalence for aspirin, beta-blockers, statins, ACE-Inhibitors, ACE-Inhibitor/ARBs and nitrates was 92% [95% confidence interval (CI): 0.89–0.95], 63% (95% CI: 0.57–0.69), 72% (95% CI: 0.60–0.82), 49% (95% CI: 0.41–0.57), 59% (95% CI: 0.48–0.69) and 79% (95% CI: 0.74–0.91), respectively. A significant increase in beta-blocker and statin use and a decrease of nitrate use was observed over time. The estimated prevalence of beta-blockers, statins, and nitrates was 78%, 91.1%, and 59.3% in 2015, compared to 32%, 17% and 96% in 1995, respectively.</p><p>Conclusion</p><p>Cardiovascular medication use after MI is far from optimal in Chinese patients, even though the prevalence of use increased over the period 1995–2015. With a rapidly increasing number of MI patients in China, a comprehensive strategy on secondary prevention is warranted.</p><p>Systematic review registration</p><p>PROSPERO (CRD42015025246)</p></div

Temporal trends in the prevalence of cardiovascular medication use.

<p>Bubbles are individual studies; diameters of the bubbles are proportional to studies weight for analysis. ACE-I: ACE-inhibitor; ARB: angiotensin receptor blocker.</p

Variables in the Original Siriraj Stroke Score.

<p>Variables in the Original Siriraj Stroke Score.</p

Flowchart of records screened and included in the systematic review.

<p>Graphical representation of the systematic search. Abbreviations in the flowchart: CENTRAL: Cochrane Register of Controlled Trials; CNKI: China National Knowledge Infrastructure.</p

Application of the Recalibrated Siriraj Stroke Score at Different Thresholds.

<p>Application of the Recalibrated Siriraj Stroke Score at Different Thresholds.</p

Baseline Characteristics.

<p>Baseline Characteristics.</p

Prevalence of aspirin by Chinese myocardial infarction patients after hospital admission.

<p>Studies followed alphabetical order. Squares and the horizontal lines represent the measures of effect (odds ratio) and associated confidence intervals for each of the studies and the diamond indicates the summary measure.</p